Journal article
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
K Weisel, A Spencer, S Lentzsch, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, A Nooka, H Quach, M Munder, C Lee, W Barreto, P Corradini, CK Min Show all
Journal of Hematology and Oncology | BMC | Published : 2020
Open access
Abstract
Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). Methods: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10-5 sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients rand..
View full abstractGrants
Funding Acknowledgements
This CASTOR study was sponsored by Janssen Research & Development, LLC.